Stryker Corp
$115.42B- Market cap
- $103.57B
- Debt
- +$15.86B
- Cash
- −$4.01B
Capital structure 87% equity / 13% debt · EV / Revenue 4.60x · EV proxy / EBITDA proxy 17.87x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $103.57B · View financials
Snapshot Sep 10, 2026, 4:00 PM ET
FY 2026 · Mkt cap
Decision snapshot: SYK stock price at premium vs MDT $270.01 current versus $206.33 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MDT's multiple
Implied fair value · at SYK's multiple
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Higher P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
13 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 87% equity / 13% debt · EV / Revenue 4.60x · EV proxy / EBITDA proxy 17.87x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
STRYKER CORP · implied price per share
Bear
$103.67
Base
$129.90
Bull
$165.28
Medtronic plc · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe SYK can sustain its 11.2% revenue growth and 14.3% ROIC without margin erosion, then hold or accumulate selectively; otherwise, the current premium versus MDT and the -39.5% P/E implied downside argue for caution because the valuation already discounts strong execution.
SYK trades at a clear valuation premium to MDT on nearly every multiples basis, which is consistent with its stronger growth and returns profile. However, the provided P/E-based implied price of $186.73 versus the current $308.84 suggests the market price is far above that framework, creating a -39.5% downside gap.
Supporting Metrics